Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Reduced Tumor Necrosis Factor Receptor–Associated Death Domain Expression Is Associated with Prostate Cancer Progression
Wang, Diping, Montgomery, Bruce , Schmidt, Lucy J., Nelson, Peter S. , Tindall, Donald J., Mostaghel, Elahe A. , Huang, Haojie

Mayo Clinic

Cancer Research | November 24, 2009 | Volume: 69 | Issue: 24 | Pages: 9448-9456

10.1158/0008-5472.can-09-1903 | PMID 19934328 Get It

Abstract By using LNCaP and its derivative cell lines, we first observed an association between tumor necrosis factor-α (TNF-α) resistance and hormone independence. Moreover, we found that the expression of tumor necrosis factor receptor–associated death domain (TRADD) was reduced in androgen deprivation–independent cells compared with that in androgen deprivation–dependent cells. TRADD is a crucial transducer for TNF-α–induced nuclear factor-κB (NF-κB) activation. Knocking down TRADD expression in LNCaP cells impaired TNF-α–induced NF-κB activation and androgen receptor repression, whereas overexpression of TRADD in C4-2B cells restored their sensitivity to TNF-α. Finally, we found that androgen deprivation reduces TRADD expression in vitro and in vivo, suggesting that androgen deprivation therapy may promote the development of TNF-α resistance by reducing TRADD expression during prostate cancer progression. [Cancer Res 2009;69(24):9448–56]
Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1
Wang, Dingyan , Stewart, A. Keith , Zhuang, Lihua, Zhu, Yuanxiao, Wang, Youdong , Shi, Chang‐Xin, Slutsky, Arthur S. , Wen, Xiao‐Yan , Keating, Armand , Zhang, Haibo , Wen, Xiao-Yan

Mayo Clinic

The FASEB Journal | November 18, 2009 | Volume: 24 | Issue: 3 | Pages: 947-956

10.1096/fj.09-140806 | PMID 19923443 Get It

Hacs1, a SH3 and SAM domain‐containing adaptor protein, is up‐regulated by IL‐4 in activated B cells and strongly expressed in dendritic cells. To elucidate the function of Hacs1 in immune regulation, we generated Hacs1 − / − mice by deletion of the SH3 and SAM domains. Hacs1 − / − mice were viable and fertile and had normal bone marrow B‐cell development and normal splenic T‐ and B‐cell populations. However, adult Hacs1 − / − mice had increased peritoneal Bla cells (IgM + CD5 + ). On immunization with T‐cell‐independent antigen TNP‐Ficoll, Hacs1 − / − mice had increased production of anti‐TNP IgM and IgG3. Purified splenic B cells from Hacs1 − / − mice showed increased cell proliferation on BCR (B‐cell receptor) stimulation. We further demonstrate that the Hacs1 − / − B cells had increased global tyrosine phosphorylation, including tyrosine kinases Lyn and Akt. Both T‐helper type 1 (T h 1) and T‐helper type 2 (T h 2) humoral responses were enhanced in Hacs1 − / − mice. In vitro bone marrow‐derived Hacs1 − / − dendritic cells showed increased IL‐12 production on stimulation with ovalbumin (OVA). This study suggests that Hacs1 is an immunoinhibitory adaptor that might be a useful target for immune suppression therapy.—Wang, D., Stewart, A. K., Zhuang, L., Zhu, Y., Wang, Y., Shi, C., Keating, A., Slutsky, A., Zhang, H., Wen, X.‐Y. Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1. FASEBJ. 24, 947–956 (20l0). www.fasebj.org
MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer
Nicoloso, Milena S. , Arvizo, Rochelle R., Wang, Enfeng , Cortez, Angelica, Calin, George A. , Bhattacharya, Resham , Rossi, Simona , Mukherjee, Priyabrata

Mayo Clinic

Cancer Research | November 10, 2009 | Volume: 69 | Issue: 23 | Pages: 9090-9095

10.1158/0008-5472.can-09-2552 | PMID 19903841 Get It

Abstract Oncogenic activation of Bmi-1 is found in a wide variety of epithelial malignancies including ovarian cancer, yet a specific mechanism for overexpression of Bmi-1 has not been determined. Thus, realizing the immense pathologic significance of Bmi-1 in cancer, we wanted to investigate if microRNA (miRNA) aberrations played a role in the regulation of Bmi-1 in ovarian cancer. In this report, we identify two miRNAs, miR-15a and miR-16, that are underexpressed in ovarian cell lines and in primary ovarian tissues. We show that these miRNAs directly target the Bmi-1 3′ untranslated region and significantly correlate with Bmi-1 protein levels in ovarian cancer patients and cell lines. Furthermore, Bmi-1 protein levels are downregulated in response to miR-15a or miR-16 expression and lead to significant reduction in ovarian cancer cell proliferation and clonal growth. These findings suggest the development of therapeutic strategies by restoring miR-15a and miR-16 expression in ovarian cancer and in other cancers that involve upregulation of Bmi-1. [Cancer Res 2009;69(23):9090–5]
Association of Breast Cancer Susceptibility Variants with Risk of Pancreatic Cancer
Couch, Fergus J., Bamlet, William R. , Petersen, Gloria M. , Wang, Xianshu , McWilliams, Robert R. , Andrade, Mariza de , Bamlet, William R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 9, 2009 | Volume: 18 | Issue: 11 | Pages: 3044-3048

10.1158/1055-9965.epi-09-0306 | PMID 19843670 Get It

AbstractBackground: A number of susceptibility genes are common to breast and pancreatic cancer. Recently, several breast cancer susceptibility loci have been identified through genome-wide association studies. Here we evaluated possible associations between these single nucleotide polymorphisms (SNP) and pancreatic cancer risk.Methods: Ten SNPs from FGFR2, TOX3, MAP3K1, H19, LSP1, chromosome 8q24, CASP8, and LUM were investigated for associations with pancreatic cancer risk following genotyping in 1,143 Caucasian individuals with pancreatic adenocarcinoma and 1,097 unaffected controls from a clinic-based pancreatic cancer case-control study.Results: CASP8 rs1045485 [odds ratio (OR), 0.78; 95% confidence interval (95% CI), 0.65-0.9; P = 0.005] and MAP3K1 rs889312 (OR, 0.85; 95% CI, 0.74-0.97; P = 0.017) showed evidence of association with risk of pancreatic cancer. The CASP8 rs1045485 association was evident in ever smokers (P = 0.002), but not in nonsmokers (P = 0.55), and the effect was strongest in heavy smokers (OR, 0.52; 95% CI, 0.29-0.93; P = 0.03). In contrast the MAP3K1 rs889312 association was only evident in nonsmokers (OR, 0.78; 95% CI, 0.64-0.95; P = 0.01). In addition, evaluation of the influence of the 10 SNPs on survival detected significant associations between outcome for locally advanced pancreatic cancer cases and both 8q rs6983561 (P = 0.045) and LUM rs2268578 (P = 0.02).Conclusion: Association studies in a large pancreatic case-control study indicate that SNPs associated with breast cancer may also be associated with pancreatic cancer susceptibility and survival. (Cancer Epidemiol Biomarkers Prev 2009;18(11):3044–8)
Noncanonical TGF-β pathways, mTORC1 and Abl, in renal interstitial fibrogenesis
Wang, Shinong, Wilkes, Mark C. , Leof, Edward B. , Hirschberg, Raimund

Mayo Clinic

American Journal of Physiology-Renal Physiology | October 21, 2009 | Volume: 298 | Issue: 1 | Pages: F142-F149

10.1152/ajprenal.00320.2009 | PMID 19846571 Get It

Renal interstitial fibrosis is a major determinant of renal failure in the majority of chronic renal diseases. Transforming growth factor-β (TGF-β) is the single most important cytokine promoting renal fibrogenesis. Recent in vitro studies identified novel non-smad TGF-β targets including p21-activated kinase-2 (PAK2), the abelson nonreceptor tyrosine kinase (c-Abl), and the mammalian target of rapamycin (mTOR) that are activated by TGF-β in mesenchymal cells, specifically in fibroblasts but less in epithelial cells. In the present studies, we show that non-smad effectors of TGF-β including PAK2, c-Abl, Akt, tuberin (TSC2), and mTOR are activated in experimental unilateral obstructive nephropathy in rats. Treatment with c-Abl or mTOR inhibitors, imatinib mesylate and rapamycin, respectively, each blocks noncanonical (non-smad) TGF-β pathways in the kidney in vivo and diminishes the number of interstitial fibroblasts and myofibroblasts as well as the interstitial accumulation of extracellular matrix proteins. These findings indicate that noncanonical TGF-β pathways are activated during the early and rapid renal fibrogenesis of obstructive nephropathy. Moreover, the current findings suggest that combined inhibition of key regulators of these non-smad TGF-β pathways even in dose-sparing protocols are effective treatments in renal fibrogenesis.
Local Excision Alone Without Irradiation for Ductal Carcinoma In Situ of the Breast: A Trial of the Eastern Cooperative Oncology Group
Hughes, Lorie L., Wang, Μolin , Page, David L., Solin, Lawrence J., Davidson, Nancy E. , Lowen, Mary Ann, Recht, Abram , Wood, William C., Gray, Robert J. , Ingle, James N.

Mayo Clinic

Journal of Clinical Oncology | October 14, 2009 | Volume: 27 | Issue: 32 | Pages: 5319-5324

10.1200/jco.2009.21.8560 | PMID 19826126 Get It

PurposeTo determine the risk of ipsilateral breast events in patients with ductal carcinoma in situ (DCIS) treated with local excision without irradiation.Patients and MethodsPatients with either low- or intermediate-grade DCIS measuring 2.5 cm or smaller, or high-grade DCIS measuring 1 cm or smaller who had microscopic margin widths of 3 mm or wider and no residual calcifications on postoperative mammograms were eligible for a prospective trial conducted from 1997 to 2002 by the Eastern Cooperative Oncology Group and North Central Cancer Treatment Group. Patients entered in 2000 and later could take tamoxifen if they wished. Median age at last surgery for the entire population was 60 years (range, 28 to 88 years), and median tumor sizes in the two strata were 6 mm and 5 mm, respectively.ResultsWith a median follow-up of 6.2 years, the 5-year rate of ipsilateral breast events in the 565 eligible patients in the low/intermediate grade stratum was 6.1% (95% CI, 4.1% to 8.2%). With a median follow-up of 6.7 years, this incidence for the 105 eligible patients in the high-grade stratum was 15.3% (95% CI, 8.2% to 22.5%).ConclusionRigorously evaluated and selected patients with low- to intermediate-grade DCIS with margins 3 mm or wider had an acceptably low rate of ipsilateral breast events at 5 years after excision without irradiation. Patients with high-grade lesions had a much higher rate, suggesting that excision alone is inadequate treatment. Further follow-up is necessary to document long-term results.
Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
Liu, Pengyuan , Wen, Weidong, James, Michael A. , Wang, Yian , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Yang, Ping , Petersen, Gloria M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Gazdar, Adi F. , Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Kupert, Elena, Lee, Juwon , Seminara, Daniela, Anderson, Marshall W., Liu, Yan , Amos, Christopher I. , Andrade, Mariza de , Minna, John Dorrance , You, Ming , Wilson, Richard K , Pinney, Susan M

Mayo Clinic

Cancer Research | September 29, 2009 | Volume: 69 | Issue: 19 | Pages: 7844-7850

10.1158/0008-5472.can-09-1833 | PMID 19789337 Get It

Abstract Recent genome-wide association studies have linked the chromosome 15q24-25.1 locus to nicotine addiction and lung cancer susceptibility. To refine the 15q24-25.1 locus, we performed a haplotype-based association analysis of 194 familial lung cases and 219 cancer-free controls from the Genetic Epidemiology of Lung Cancer Consortium (GELCC) collection, and used proliferation and apoptosis analyses to determine which gene(s) in the 15q24-25.1 locus mediates effects on lung cancer cell growth in vitro. We identified two distinct subregions, hapL (P = 3.20 × 10−6) and hapN (P = 1.51 × 10−6), which were significantly associated with familial lung cancer. hapL encompasses IREB2, LOC123688, and PSMA4, and hapN encompasses the three nicotinic acetylcholine receptor subunit genes CHRNA5, CHRNA3, and CHRNB4. Examination of the genes around hapL revealed that PSMA4 plays a role in promoting cancer cell proliferation. PSMA4 mRNA levels were increased in lung tumors compared with normal lung tissues. Down-regulation of PSMA4 expression decreased proteasome activity and induced apoptosis. Proteasome dysfunction leads to many diseases including cancer, and drugs that inhibit proteasome activity show promise as a form of cancer treatment. Genes around hapN were also investigated, but did not show any direct effect on lung cancer cell proliferation. We concluded that PSMA4 is a strong candidate mediator of lung cancer cell growth, and may directly affect lung cancer susceptibility through its modulation of cell proliferation and apoptosis. [Cancer Res 2009;69(19):7844–50]
MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma
Yang, Hushan , Gu, Jian , Wang, Kenneth K. , Zhang, Wei , Xing, Jinliang , Wu, Xifeng , Chen, Zhi‐Nan , Ajani, Jaffer A. , Gu, Jian

Mayo Clinic

Clinical Cancer Research | September 8, 2009 | Volume: 15 | Issue: 18 | Pages: 5744-5752

10.1158/1078-0432.ccr-09-0385 | PMID 19737949 Get It

Abstract Purpose: Esophageal adenocarcinoma is a highly aggressive malignancy that frequently develops from Barrett's esophagus, a premalignant pathologic change occurring in the lower end of the esophagus. Identifying Barrett's esophagus patients at high risk of malignant transformation is essential to the prevention of esophageal adenocarcinoma. Although microRNA (miRNA) expression signatures have been associated with the etiology and prognosis of several types of cancers, their roles in the development of esophageal adenocarcinoma have not been extensively evaluated. Experimental Design: In this study, we analyzed the expression patterns of 470 human miRNAs using Agilent miRNA microarray in 32 disease/normal-paired tissues from 16 patients diagnosed with Barrett's esophagus of either low- or high-grade dysplasia, or esophageal adenocarcinoma. Results: Using unsupervised hierarchical clustering and class comparison analyses, we found that miRNA expression profiles in tissues of Barrett's esophagus with high-grade dysplasia were significantly different from their corresponding normal tissues. Similar findings were observed for esophageal adenocarcinoma, but not for Barrett's esophagus with low-grade dysplasia. The expression patterns of selected miRNAs were further validated using quantitative reverse transcription real-time PCR in an independent set of 75 pairs of disease/normal tissues. Finally, we identified several miRNAs that were involved in the progressions from low grade-dysplasia Barrett's esophagus to esophageal adenocarcinoma. Conclusions: We showed that miRNAs were involved in the development and progression of esophageal adenocarcinoma. The identified significant miRNAs that may become potential targets for early detection, chemoprevention, and treatment of esophageal cancer. (Clin Cancer Res 2009;15(18):5744–52)
Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-β for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy
Saloura, Vassiliki , Wang, Liang‐Chuan S., Fridlender, Zvi G., Sun, Jing , Cheng, Guanjun, Kapoor, Veena, Sterman, Daniel H. , Harty, Ronald N. , Okumura, Atsushi , Barber, Glen N. , Vile, Richard G. , Federspiel, Mark J. , Russell, Stephen J. , Litzky, Leslie A., Albelda, Steven Μ. , Russell, Stephen J

Mayo Clinic

Human Gene Therapy | August 28, 2009 | Volume: 21 | Issue: 1 | Pages: 51-64

10.1089/hum.2009.088 | PMID 19715403 Get It

Short- and Long-Term Risk Stratification Using a Next-Generation, High-Sensitivity Research Cardiac Troponin I (hs-cTnI) Assay in an Emergency Department Chest Pain Population
Kavsak, Peter A. , Ko, Dennis T. , MacRae, Andrew R., Jaffe, Allan S. , Wang, Xuesong , Jaffe, Allan S. , Kavsak, Peter

Mayo Clinic

Clinical Chemistry | August 13, 2009 | Volume: 55 | Issue: 10 | Pages: 1809-1815

10.1373/clinchem.2009.127241 | PMID 19679630 Get It

Abstract Background: The next-generation, high-sensitivity cardiac troponin assays can measure quantifiable concentrations of cTn in a majority of individuals, but there are few studies assessing these assays for risk stratification. The present study was undertaken to determine if a research hs-cTnI assay can be useful for predicting death/myocardial infarction (MI), both short- and long-term, in an emergency department acute coronary syndrome (ACS) population. Methods: In a cohort of 383 subjects, originally recruited in 1996, presenting to the emergency department with symptoms suggestive of ACS, the heparin plasma obtained at initial presentation was thawed and measured in 2007 with a research hs-cTnI assay. AccuTnI (Beckman Coulter) measurements were made on these same samples in 2003. The population was divided into 4 groups by hs-cTnI: <5.00, 5.00–9.99, 10.00–40.00, and >40.00 ng/L. Kaplan–Meier, Cox proportional hazards, ROC curves, and logistic regression analyses were used to identify which hs-cTnI concentrations were predictive of death/MI within 10 years after presentation. Results: There were significant differences between the hs-cTnI groups for the probability of death/MI up to 10 years after presentation (P < 0.05). At 6 months, patients with hs-cTnI ≥10.00 ng/L were at higher risk for death/MI (hazard ratio >3.7; P < 0.05) compared with those having hs-cTnI <5.00 ng/L. ROC curve analysis for death/MI at 30 days with the hs-cTnI assay had an area under the curve of 0.74 (95% CI 0.65–0.82), with logistic models yielding an optimal assay threshold of 12.68 ng/L. Conclusions: This research hs-cTnI assay appears useful for risk stratification for death/MI in an ACS population.